{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-003429","form_type":"8-K","ticker":"EDSA","cik":"0001540159","company_name":"Edesa Biotech, Inc.","filed_at":"2026-05-14T20:40:19+00:00","discovered_at":"2026-05-14T20:41:00.270887+00:00","generated_at":"2026-05-14T20:41:19.838089+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Edesa Biotech Q2 net loss widens to $4.2M; progresses EB06 vitiligo Phase 2 prep","bullets":["Net loss of $4.2M ($0.49/sh) for Q2 FY2026 vs $1.6M ($0.30/sh) in prior year.","Operating expenses rose $2.7M to $4.3M on $2.3M R&D increase for EB06 and paridiprubart prep.","Cash and cash equivalents $10.0M; working capital $8.2M as of March 31, 2026.","EB06 Phase 2 vitiligo study on track; site activations and recruitment expected mid-2026 subject to approval.","Paridiprubart Phase 3 ARDS data showed consistent treatment benefits across disease subgroups and comorbidities."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-003429","json":"https://secwatch.observer/filing/0001171843-26-003429.json","markdown":"https://secwatch.observer/filing/0001171843-26-003429.md","text":"https://secwatch.observer/filing/0001171843-26-003429.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540159/000117184326003429/0001171843-26-003429-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540159/000117184326003429/f8k_051326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:41:19.838089+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b10cf5c860d620b059bf32c33de04ba4af284a19","claim":"Edesa Biotech, Inc. reported the three months ended March 31, 2026 results: net income a net loss of $4.2 million, or $0.49 per common share, EPS $0.49 per common share.","evidence_excerpt":"For the quarter ended March 31, 2026, Edesa reported a net loss of $4.2 million, or $0.49 per common share, compared to a net loss of $1.6 million, or $0.30 per common share, for the quarter ended March 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1540159/000117184326003429/0001171843-26-003429-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2026"},{"label":"Net income","value":"a net loss of $4.2 million, or $0.49 per common share"},{"label":"EPS","value":"$0.49 per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e47acf66d806ca7c6e5ed0d7332590bc8614dd05","claim":"Edesa Biotech, Inc. reported the six months ended March 31, 2026 results: net income a net loss of $6.5 million, or $0.78 per common share, EPS $0.78 per common share.","evidence_excerpt":"For the six months ended March 31, 2026, Edesa reported a net loss of $6.5 million, or $0.78 per common share, compared to a net loss of $3.2 million, or $0.74 per common share, for the six months ended March 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1540159/000117184326003429/0001171843-26-003429-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the six months ended March 31, 2026"},{"label":"Net income","value":"a net loss of $6.5 million, or $0.78 per common share"},{"label":"EPS","value":"$0.78 per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}